Shots:
- AbCellera will receive equity and research fees and is eligible to receive milestone along with royalties based on the development and commercialization of Abs
- Angios gets the rights to develop and commercialize therapeutic products resulting from the collaboration
- AbCellera will use an AI-powered platform to generate panels of Abs for up to three Angios-selected targets against diabetic retinopathy
Click here to read full press release/ article | Ref: BUSINESS WIRE| Image: AbCellera
The post AbCellera Signs a Multi-Target Collaboration with Amgen to Develop Bispecific Antibodies for the Treatment of Diabetic Retinopathy first appeared on PharmaShots.
